Приказ основних података о документу

dc.creatorPetrou, Anthi
dc.creatorGeronikaki, Athina
dc.creatorKartsev, Victor
dc.creatorKousaxidis, Antonios
dc.creatorPapadimitriou-Tsantarliotou, Aliki
dc.creatorKostić, Marina
dc.creatorIvanov, Marija
dc.creatorSoković, Marina
dc.creatorNicolaou, Ioannis
dc.creatorVizirianakis, Ioannis S.
dc.date.accessioned2023-03-03T11:59:47Z
dc.date.available2023-03-03T11:59:47Z
dc.date.issued2023
dc.identifier.issn1424-8247
dc.identifier.urihttps://www.mdpi.com/1424-8247/16/1/131
dc.identifier.urihttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC9865890
dc.identifier.urihttp://radar.ibiss.bg.ac.rs/handle/123456789/5459
dc.description.abstractHerein, we report the experimental evaluation of the antimicrobial activity of seventeen new (Z)-methyl 3-(4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-1H-indole-2-carboxylate derivatives. All tested compounds exhibited antibacterial activity against eight Gram-positive and Gram-negative bacteria. Their activity exceeded those of ampicillin as well as streptomycin by 10-50 fold. The most sensitive bacterium was En. Cloacae, while E. coli was the most resistant one, followed by M. flavus. The most active compound appeared to be compound 8 with MIC at 0.004-0.03 mg/mL and MBC at 0.008-0.06 mg/mL. The antifungal activity of tested compounds was good to excellent with MIC in the range of 0.004-0.06 mg/mL, with compound 15 being the most potent. T. viride was the most sensitive fungal, while A. fumigatus was the most resistant one. Docking studies revealed that the inhibition of E. coli MurB is probably responsible for their antibacterial activity, while 14a-lanosterol demethylase of CYP51Ca is involved in the mechanism of antifungal activity. Furthermore, drug-likeness and ADMET profile prediction were performed. Finally, the cytotoxicity studies were performed for the most active compounds using MTT assay against normal MRC5 cells.
dc.publisherBasel: MDPI
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200007/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcePharmaceuticals
dc.subjectADMET
dc.subjectantibacterial activity
dc.subjectantifungal activity
dc.subjectantimicrobial
dc.subjectcytotoxicity
dc.subjectindole
dc.subjectmolecular docking
dc.subjectrhodanine
dc.titleN-Derivatives of (Z)-Methyl 3-(4-Oxo-2-thioxothiazolidin-5-ylidene)methyl)-1H-indole-2-carboxylates as Antimicrobial Agents-In Silico and In Vitro Evaluation
dc.typearticleen
dc.rights.licenseBY
dc.rights.holder©2023 by the authors. Licensee MDPI, Basel, Switzerland.
dc.citation.issue1
dc.citation.volume16
dc.identifier.doi10.3390/ph16010131
dc.identifier.pmid36678628
dc.identifier.scopus2-s2.0-85146812650
dc.identifier.wos000918911300001
dc.citation.apaPetrou, A., Geronikaki, A., Kartsev, V., Kousaxidis, A., Papadimitriou-Tsantarliotou, A., Kostic, M., et al. (2023). N-Derivatives of (Z)-Methyl 3-(4-Oxo-2-thioxothiazolidin-5-ylidene)methyl)-1H-indole-2-carboxylates as Antimicrobial Agents-In Silico and In Vitro Evaluation. Pharmaceuticals, 16(1), 131.
dc.citation.vancouverPetrou A, Geronikaki A, Kartsev V, Kousaxidis A, Papadimitriou-Tsantarliotou A, Kostic M, Ivanov M, Sokovic M, Nicolaou I, Vizirianakis IS. N-Derivatives of (Z)-Methyl 3-(4-Oxo-2-thioxothiazolidin-5-ylidene)methyl)-1H-indole-2-carboxylates as Antimicrobial Agents-In Silico and In Vitro Evaluation. Pharmaceuticals. 2023;16(1):131.
dc.citation.spage131
dc.type.versionpublishedVersion
dc.identifier.fulltexthttps://radar.ibiss.bg.ac.rs/bitstream/id/12401/pharmaceuticals-16-00131.pdf
dc.citation.rankM21~


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу